AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
July 10 2017 - 6:56AM
Lausanne, Switzerland, July 10, 2017 - AC
Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage
biopharmaceutical company focused on neurodegenerative diseases,
today announced that seven updates on the advancement of its
in-house and partnered product candidates and technology platforms
will be provided at the Alzheimer's Association International
Conference (AAIC 2017©). The conference is the largest
international meeting dedicated to advancing dementia science and
takes place in London, UK from July 15th to July 20th, 2017.
Program and Collaborator |
Presentations and Timing |
Crenezumab / Genentech |
Mathematical model of amyloid beta dynamics to assess target
engagement of soluble amyloid beta oligomers by crenezumab in the
Alzheimer's disease brain Poster - July 16 / 9:30 - 16:15 (S8,
P109) Safety and tolerability of crenezumab in mild-to-moderate
AD patients treated with escalating doses for up to 25 months
Oral presentation - July 17 / 17:30 - 17:45 (N10
) |
anti-Tau antibody /Genentech |
Changes in Tau protein landscape during Alzheimer's disease
progression Poster - July 19 / 9:30 - 16:15 (S8) A Phase 1
Study to evaluate the safety and tolerability of RO7105705 in
healthy volunteers and patients with mild-to-moderate AD Oral
Presentation - July 17 / 16:45 - 17:00 (N10, P99) |
Tau-PET imaging agent / Piramal
|
First in human PET studies with the next generation Tau agent
18F-PI-2620 in Alzheimer's disease, progressive supranuclear palsy
and controls Oral Presentation - July 15 / 10:00 - 10:15
(S10-C) Preclinical characterization of PI-2620, a novel
Tau-PET-tracer for detection of Tau in AD and other Tauopathies
Poster - July 15 / 12:15 - 13:30 (S9, P192)
Preclinical Characterization of PI-2620, a Novel Tau PET Tracer for
detection of Tau in AD and other Tauopathies Poster - July 17 /
9:30- 16:15 (S8, P381) |
AC Immune vaccine technology |
Development of highly sensitive MSD assays for the detection of
anti-amyloid beta monomer and oligomer-specific antibodies in human
serum Poster - July 18 / 9:30-16:15 (S8, P67) |
About AC ImmuneAC Immune is a clinical stage
Swiss-based biopharmaceutical company focused on neurodegenerative
diseases with four product candidates in clinical trials. The
Company designs, discovers and develops therapeutic and diagnostic
products intended to prevent and modify diseases caused by
misfolding proteins. AC Immune's two proprietary technology
platforms create antibodies, small molecules and vaccines designed
to address a broad spectrum of neurodegenerative indications, such
as Alzheimer's disease. The Company's pipeline features seven
therapeutic and three diagnostic product candidates. The most
advanced of these is crenezumab, an anti-Abeta antibody in phase 3
clinical studies that is being advanced by the collaboration
partner Genentech, Inc., a wholly owned subsidiary of Roche. Other
business partners include Biogen, Janssen Pharmaceuticals, Nestlé
Institute of Health Sciences, Piramal Imaging and Essex
Bio-Technology.
Forward looking statementsThis press
release contains statements that constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements are statements other than historical
fact and may include statements that address future operating,
financial or business performance or AC Immune's strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may," "might," "will," "should,"
"expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "outlook" or "continue," and
other comparable terminology. Forward-looking statements are based
on management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include those described under the captions "Item 3.
Key Information-Risk Factors" and "Item 5. Operating and Financial
Review and Prospects" in AC Immune's Annual Report on Form 20-F and
other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made,
and AC Immune does not undertake any obligation to update them in
light of new information, future developments or otherwise, except
as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
For further information please
contact:
Prof. Andrea PfeiferChief Executive OfficerPhone: +41 21 345 91
21E-mail: andrea.pfeifer@acimmune.com |
Eva SchierCorporate Communications ManagerPhone: +41 21 345 91
34Mobile: +41 79 926 66 03E-mail: eva.schier@acimmune.com
|
Nick Miles/Toomas Kull Cabinet Privé de Conseils s.a.Phone: +41 22
552 46 46 E-mail: miles@cpc-pr.com kull@cpc-pr.com
|
In the USTed AgneThe Communications Strategy Group
Inc.Phone: +1 781 631 3117E-mail: edagne@comstratgroup.com
|
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/970f6a38-142a-4f8b-b6b3-334c2c99749c
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Apr 2024 to May 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From May 2023 to May 2024